167. マルファン症候群 Marfan syndrome Clinical trials / Disease details
臨床試験数 : 21 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00782327 (ClinicalTrials.gov) | November 1, 2009 | 29/10/2008 | Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers | Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers | Marfan Syndrome | Drug: Losartan;Drug: Placebo | University Hospital, Ghent | Agentschap voor Innovatie door Wetenschap en Technologie | Completed | 10 Years | N/A | All | 22 | Phase 3 | Belgium |
| 2 | EUCTR2007-005862-10-BE (EUCTR) | 29/05/2009 | 07/01/2009 | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Marfan syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: Cozaar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium | University Hospital Ghent | NULL | Not Recruiting | Female: yes Male: yes | Belgium | ||||
| 3 | EUCTR2008-001462-81-IT (EUCTR) | 27/10/2008 | 17/03/2008 | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND | Marfan Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: LORTAAN*28CPR RIV DIV 50MG INN or Proposed INN: Losartan Trade Name: LOBIVON*28CPR 5MG INN or Proposed INN: Nebivolol | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Italy | |||
| 4 | NCT01145612 (ClinicalTrials.gov) | October 2008 | 15/6/2010 | Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome | A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Losartan;Drug: Atenolol | Forteza, Albert, M.D. | Ministry of Health, Spain | Active, not recruiting | 5 Years | 60 Years | Both | 140 | Phase 3 | Spain |
| 5 | NCT00763893 (ClinicalTrials.gov) | September 2008 | 30/9/2008 | Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome | Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome | Marfan Syndrome | Drug: placebo;Drug: Losartan | Assistance Publique - Hôpitaux de Paris | NULL | Terminated | 10 Years | N/A | Both | 303 | Phase 3 | France |
| 6 | NCT00683124 (ClinicalTrials.gov) | July 2008 | 21/5/2008 | Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients | Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations. | Marfan Syndrome | Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol | IRCCS Policlinico S. Matteo | Merck Sharp & Dohme Corp.;Menarini Group | Recruiting | 12 Months | 55 Years | Both | 291 | Phase 3 | Italy |
| 7 | EUCTR2007-001125-97-ES (EUCTR) | 20/05/2008 | 03/12/2007 | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: cozaar 50 INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: blokium 50 INN or Proposed INN: ATENOLOL Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: BLOKIUM 50 mg comprimidos INN or Proposed INN: ATENOLOL | alberto forteza | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
| 8 | NCT00593710 (ClinicalTrials.gov) | January 2008 | 3/1/2008 | Losartan Versus Atenolol for the Treatment of Marfan Syndrome | A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan;Drug: Atenolol | University of British Columbia | Heart and Stroke Foundation of Canada | Completed | 12 Years | 25 Years | Both | 17 | Phase 2 | Canada |
| 9 | NCT00723801 (ClinicalTrials.gov) | October 2007 | 25/7/2008 | Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome | Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome | Marfan Syndrome | Drug: Atenolol;Drug: Losartan | Brigham and Women's Hospital | Boston Children’s Hospital | Completed | 25 Years | N/A | All | 40 | Phase 3 | United States |
| 10 | NCT00651235 (ClinicalTrials.gov) | February 2007 | 3/3/2008 | A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan and Atenolol or Propranolol;Drug: Atenolol or Propranolol | National Taiwan University Hospital | NULL | Recruiting | 1 Year | N/A | Both | 44 | Phase 2 | Taiwan |
| 11 | NCT00429364 (ClinicalTrials.gov) | January 2007 | 29/1/2007 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) | Marfan Syndrome | Drug: Losartan Potassium;Drug: Atenolol | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan Foundation | Completed | 6 Months | 25 Years | All | 608 | Phase 3 | United States;Belgium;Canada |
| 12 | EUCTR2006-003991-37-BE (EUCTR) | 13/12/2006 | 06/12/2006 | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Marfan syndrome MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol | University Hospital Gent | NULL | Not Recruiting | Female: yes Male: yes | 600 | Belgium |